相关实验视频

Updated: Jun 14, 2025

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

2D差异金属免疫增强剂驱动抗原特异性免疫对瘤的高多样性和能力

Hongze Ren^1,2, Anqi Zhu³, Wei Yang⁴

¹Materdicine Lab, School of Life Sciences, Shanghai University, Shanghai, 200444, China.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)

|September 3, 2024

概括

使用和纳米片 (MANS-H) 的新型癌症疫苗有效地提高了对瘤的免疫反应. 这种新疫苗促进T细胞和抗体的产生,导致在临床前模型中显著的瘤回归.

科学领域:

生物技术是生物技术.
免疫学免疫学免疫学
材料科学材料科学材料科学

背景情况:

目前的癌症疫苗治疗效果有限.
需要改进的疫苗辅助剂来增强抗瘤免疫力.

研究的目的:

开发和评估一个合理设计的癌症疫苗,利用2D纳米板 (NS) 架构.
为了研究-纳米板 (MANS-H) 辅助剂的免疫调节作用.

主要方法:

制造2D纳米板 (NS) 架构,结合临床批准的 (Al) 或 (Mn) 与抗原.
描述MANS-H结构及其免疫调节特性.
评估疫苗在促进先天性和适应性免疫反应,包括T细胞和抗体产生方面的疗效,以及体内瘤回归模型.

主要成果:

该MANS-H辅助剂显著促进了先天性免疫细胞的透,并刺激了各种树突细胞子集.
MANS-H增强了抗原特异性T细胞反应 (Th1,CD8+) 和抗体产生,表现优于商业辅助剂.
用MANS-H辅助疫苗接种疫苗导致了强大的瘤回归,并在侵略性癌症模型中克服了瘤抵抗力.

结论:

工程设计的MANS-H辅助剂显示出癌症免疫治疗的巨大潜力.
独特的NS架构和安全的免疫增强剂为临床癌症疫苗开发提供了一个有希望的下一步.

关键词:

2D纳米薄膜可以使用.抗原特异性免疫的免疫力癌症免疫疗法免疫疗法癌症疫苗癌症疫苗材料辅助剂材料辅助剂

更多相关视频

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.